Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN N ALLAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1144462441
CMS profile
142657
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$127,444.54

113 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN N ALLAN

NPI 1144462441 · CMS profile ID 142657

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144462441?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN N ALLAN, NPI 1144462441, CMS profile ID 142657. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144462441?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOHN N ALLAN, NPI 1144462441, CMS profile ID 142657. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144462441?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOHN N ALLAN, NPI 1144462441, CMS profile ID 142657, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1144462441?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

113 matching records · $127,444.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 113 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–113 of 113.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $29.8703/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890488081 CMS
Seagen Inc. $34.6603/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904090893 CMS
Janssen Scientific Affairs, LLC $720.0003/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887282809 CMS
Janssen Global Services, LLC $400.0003/15/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887128073 CMS
AstraZeneca Pharmaceuticals LP $125.0403/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920257139 CMS
Janssen Global Services, LLC $930.0003/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887128055 CMS
Janssen Biotech, Inc. $133.5203/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886278776 CMS
BeiGene USA, Inc. $5,850.0002/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940794213 CMS
BeiGene USA, Inc. $507.2002/24/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940794215 CMS
BeiGene USA, Inc. $95.4102/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940794217 CMS
BeiGene USA, Inc. $227.7702/24/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940794219 CMS
BeiGene USA, Inc. $288.0902/24/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940794221 CMS
Genentech USA, Inc. $1,650.0002/24/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950687029 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $41,769.45 64
PY2020 $40,426.30 40
PY2021 $93,595.97 73
PY2022 $127,444.54 113
PY2023 $157,099.54 129
PY2024 $51,982.70 64
PY2025 $67,729.42 52

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,300.60 4
PY2025 Principal investigator $1,024,845.54 45
PY2024 Recipient $3,509.42 7
PY2024 Principal investigator $642,794.79 41
PY2023 Principal investigator $1,319,090.81 52
PY2022 Recipient $3,786.08 1
PY2022 Principal investigator $332,030.28 67
PY2021 Recipient $15.58 1
PY2021 Principal investigator $367,356.50 58
PY2020 Recipient $2,373.07 4
PY2020 Principal investigator $592,850.26 29
PY2019 Recipient $1,360.60 6
PY2019 Principal investigator $1,071,109.99 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,691.61 12/11/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184270209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,279.79 11/20/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184263281
Principal investigator 1 BeOne Medicines Ltd. $5,262.76 10/23/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330617
Principal investigator 1 BeOne Medicines Ltd. $5,262.76 10/23/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,504.72 10/15/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184250079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $338,356.45 10/09/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184249216
Recipient Regeneron Pharmaceuticals, Inc. $351.61 10/02/2025 Covered Recipient Physician AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184115023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,334.12 09/18/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184240170
Principal investigator 1 BeOne Medicines USA, Inc. $33,040.00 09/08/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333916
Principal investigator 1 ABBVIE INC. $823.54 09/01/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UN
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 1202506881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,830.63 08/13/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184226917
Recipient Regeneron Pharmaceuticals, Inc. $156.56 07/29/2025 Covered Recipient Physician AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184115021
Principal investigator 1 BeOne Medicines USA, Inc. $14,241.00 07/28/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190332219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,530.97 07/23/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184218017
Principal investigator 1 BeOne Medicines Ltd. $50,304.00 07/21/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190337753
Principal investigator 1 BeOne Medicines Ltd. $624.25 07/14/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330551
Principal investigator 1 BeOne Medicines Ltd. $1,248.50 07/14/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330553
Principal investigator 1 BeOne Medicines Ltd. $5,262.76 07/14/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330555
Principal investigator 1 BeOne Medicines Ltd. $1,248.50 07/14/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330557
Principal investigator 1 BeOne Medicines Ltd. $8,612.72 07/14/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330559
Principal investigator 1 BeOne Medicines Ltd. $5,262.76 07/14/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330561
Principal investigator 1 BeOne Medicines Ltd. $624.25 07/14/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330563
Principal investigator 1 BeOne Medicines Ltd. $8,612.72 07/14/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330565
Principal investigator 1 ABBVIE INC. $10,500.00 07/08/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UN
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 1202497506
Principal investigator 1 ABBVIE INC. $2,040.00 07/08/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UN
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 1202497508
Principal investigator 1 ABBVIE INC. $4,000.00 07/08/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UN
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 1202497510
Principal investigator 1 BeOne Medicines Ltd. $33,536.00 07/07/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330535
Principal investigator 1 BeOne Medicines USA, Inc. $3,389.00 07/07/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190332215
Principal investigator 1 BeOne Medicines USA, Inc. $4,231.00 07/07/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190332217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56,379.93 06/13/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184206741
Principal investigator 1 BeOne Medicines Ltd. $10,314.00 05/29/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80,202.45 05/28/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184198793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,000.00 05/08/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184193693
Principal investigator 1 BeiGene, Ltd. $8,241.00 04/28/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190325498
Principal investigator 1 ABBVIE INC. $516.91 03/18/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UN
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 1202464257
Recipient Regeneron Pharmaceuticals, Inc. $228.00 03/08/2025 Covered Recipient Physician AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184115019
Principal investigator 1 BeiGene, Ltd. $8,731.00 03/03/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190325496
Principal investigator 1 BeiGene, Ltd. $40,438.00 02/24/2025 Non-covered Recipient Entity
Weill Cornell Medical College
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190325494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,650.52 02/20/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184155054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,871.92 02/06/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184152664
Recipient Regeneron Pharmaceuticals, Inc. $4,564.43 01/11/2025 Covered Recipient Physician AN OPEN-LABEL, MULTI-CENTER PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, IN PATIENTS WITH CD20+ B-CELL MALIGNANCIES PREVIOUSLY TREATED WITH CD20-DIRECTED ANTIBODY THERAPY (ELM-1) No dispute reported 06/30/2026 1184115017
Principal investigator 1 ABBVIE INC. $37,250.60 01/09/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UN
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1202437361
Principal investigator 1 ABBVIE INC. $3,500.00 01/09/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UN
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1202437365
Principal investigator 1 ABBVIE INC. $7,750.00 01/09/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UN
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1202437369
Principal investigator 1 ABBVIE INC. $1,726.25 01/09/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UN
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1202437373
Principal investigator 1 ABBVIE INC. $1,500.00 01/09/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UN
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1202437377
Principal investigator 1 ABBVIE INC. $13,000.00 01/09/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UN
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1202437381
Principal investigator 1 ABBVIE INC. $2,500.00 01/09/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEGE OF CORNELL UN
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1202437385
Principal investigator 1 Genentech, Inc. $120,618.15 01/02/2025 Non-covered Recipient Entity
WEILL MEDICAL COLLEG
Polatuzumab vedotin alone or in combination with chemotherapy in patients with Richter s Transforma No dispute reported 06/30/2026 1211684724